Copyright © 2015 - 2022 Lifecarenews.in
LIFE CARE IS REGISTERED MAGAZINE IN RNI, NO.GUJGUJ/2015/71283
Harpoon Therapeutics to Participate in the Canaccord
SOUTH SAN FRANCISCO, Calif., April 10, 2023 (GLOBE NEWSWIRE) --…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Harpoon
Harpoon Therapeutics Reports Fourth Quarter and Full Year
HPN217 (BCMA) and HPN328 (DLL3) enrollment on track, with data…
Harpoon Therapeutics Announces Acceptance of Five Abstracts
<!-- Name:DistributionId Value:8788460 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->
<!-- Name:IcbCode Value:4573 -->…
Harpoon Therapeutics Presents Updated Interim Results at
Clinically active across a wide dose range (2.15 to 24 mg) in a Phase 1 trial of heavily pretreated patients with relapsed/refractory multiple myeloma77% (10/13) objective response rate (ORR) observed across highest doses (12 and 24 mg)…